Who
Merdad Parsey
Director
Company insider
Files Form 4 as: Director, ArriVent BioPharma; Director, Ardelyx; Chief Medical Officer, Gilead Sciences; Director, Sagimet Biosciences.
In numbers
- Trades disclosed
- 132
- Buys
- 0
- Sells
- 14
- Bought
- $0
- Sold
- $22.2M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 10 Nov 2019
- Last trade
- 18 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 22 Jun 2026 | AVBP ArriVent BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,562 at $0.00 | filing |
| 18 Jun 2026filed 22 Jun 2026 | AVBP ArriVent BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,562 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Code A | —26,455 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | ARDX Ardelyxoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,715 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | ARDX Ardelyxoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,715 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Code A | —26,455 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | ARDX ArdelyxBiotechnology | SEC FORM 4 Code A | —15,235 at $0.00 | filing |
| 18 Jun 2025filed 20 Jun 2025 | AVBP ArriVent BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,502 at $0.00 | filing |
| 28 Apr 2025filed 14 May 2025 | ARDX Ardelyxoption or derivative · Biotechnology | SEC FORM 4 Code A | —64,457 at $0.00 | filing |
| 28 Apr 2025filed 14 May 2025 | ARDX ArdelyxBiotechnology | SEC FORM 4 Code A | —42,056 at $0.00 | filing |
| 28 Apr 2025filed 29 Apr 2025 | AVBP ArriVent BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,346 at $0.00 | filing |
| 10 Dec 2024filed 11 Dec 2024 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,820 | filing |
| 10 Dec 2024filed 11 Dec 2024 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code M | —3,820 | filing |
| 10 Dec 2024filed 11 Dec 2024 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code F | $164K1,771 at $92.34 | filing |
| 27 Nov 2024filed 29 Nov 2024 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —57,294 at $0.00 | filing |
| 27 Nov 2024filed 29 Nov 2024 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —88,119 at $0.00 | filing |
| 27 Nov 2024filed 29 Nov 2024 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code M | $3.3M57,294 at $57.92 | filing |
| 27 Nov 2024filed 29 Nov 2024 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code M | $5.8M88,119 at $65.38 | filing |
| 27 Nov 2024filed 29 Nov 2024 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $5.3M57,294 at $91.79 | filing |
| 27 Nov 2024filed 29 Nov 2024 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $8.1M88,119 at $92.00 | filing |
News
Sofinnova Investments Announces the Appointment of Dr. Merdad Parsey as Executive Partnerrutlandherald.com · 9 Sep 2026Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?GILD · fool.com · 18 Oct 2026Gilead Sciences Clears Its February High at $153.54GILD · 247wallst.com · 15 Oct 2026Gilead Sciences, Inc. $GILD Stock Acquired by First Citizens Bank & Trust Co.GILD · dailypolitical.com · 14 Oct 2026
1 headline in the last 90 days name Merdad Parsey; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.